MX2021013971A - Regimen de dosificacion de eltrombopag. - Google Patents

Regimen de dosificacion de eltrombopag.

Info

Publication number
MX2021013971A
MX2021013971A MX2021013971A MX2021013971A MX2021013971A MX 2021013971 A MX2021013971 A MX 2021013971A MX 2021013971 A MX2021013971 A MX 2021013971A MX 2021013971 A MX2021013971 A MX 2021013971A MX 2021013971 A MX2021013971 A MX 2021013971A
Authority
MX
Mexico
Prior art keywords
eltrombopag
dosage regime
itp
administering
patient
Prior art date
Application number
MX2021013971A
Other languages
English (en)
Spanish (es)
Inventor
Miona Stankovic
Nichola Cooper
Waleed Ghanima
Francesco Zaja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021013971A publication Critical patent/MX2021013971A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021013971A 2019-05-14 2019-05-14 Regimen de dosificacion de eltrombopag. MX2021013971A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/032171 WO2020231407A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen

Publications (1)

Publication Number Publication Date
MX2021013971A true MX2021013971A (es) 2022-04-01

Family

ID=67211802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013971A MX2021013971A (es) 2019-05-14 2019-05-14 Regimen de dosificacion de eltrombopag.

Country Status (9)

Country Link
US (1) US20220313663A1 (cg-RX-API-DMAC7.html)
EP (1) EP3968984A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022537883A (cg-RX-API-DMAC7.html)
KR (1) KR20220035036A (cg-RX-API-DMAC7.html)
AU (2) AU2019445762A1 (cg-RX-API-DMAC7.html)
CA (1) CA3140137A1 (cg-RX-API-DMAC7.html)
IL (1) IL288078A (cg-RX-API-DMAC7.html)
MX (1) MX2021013971A (cg-RX-API-DMAC7.html)
WO (1) WO2020231407A1 (cg-RX-API-DMAC7.html)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201406373A (zh) * 2012-06-29 2014-02-16 Shionogi & Co 含有具有血栓形成素受體促效作用之化合物之醫藥組合物

Also Published As

Publication number Publication date
JP2023182667A (ja) 2023-12-26
AU2019445762A1 (en) 2021-12-09
AU2023274065A1 (en) 2023-12-14
JP2022537883A (ja) 2022-08-31
US20220313663A1 (en) 2022-10-06
IL288078A (en) 2025-01-01
CA3140137A1 (en) 2020-11-19
WO2020231407A1 (en) 2020-11-19
KR20220035036A (ko) 2022-03-21
EP3968984A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
CL2019002204A1 (es) Compuestos inhibidores del vih.
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
MX387115B (es) Métodos para tratar la influenza.
EA201890735A1 (ru) Модуляторы корового белка вируса гепатита b
MX389672B (es) Inhibidores de ssao de aminopirimidina
MX391812B (es) Agonista fxr derivado de esteroides.
SV2018005682A (es) Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
EA201791576A1 (ru) Ингибитор jak
MX2019001814A (es) Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
MX2017003414A (es) Terapia de combinacion para alzheimer que usa anticuerpos abeta anti-n3pglu + un inhibidor de bace.
PH12019501955A1 (en) Tri-cycle compound and applications thereof
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2022005522A (es) Formas de sal de un receptor de componente c5a de complemento.
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201991688A1 (ru) Фармацевтические комбинации для лечения рака
MX380758B (es) Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MX2019014291A (es) Metodo de tratamiento.
EA202193276A1 (ru) Способы лечения холангиокарциномы
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
MX2022005245A (es) Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer.